Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice

[1]  Oliver Wildner,et al.  Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice , 2013, Virology Journal.

[2]  S. Himanen,et al.  AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland , 2012, PloS one.

[3]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[4]  K. Überla,et al.  Vaccination with an Adenoviral Vector That Encodes and Displays a Retroviral Antigen Induces Improved Neutralizing Antibody and CD4+ T-Cell Responses and Confers Enhanced Protection , 2009, Journal of Virology.

[5]  Y. Shoenfeld,et al.  Adjuvants and autoimmunity , 2009, Lupus.

[6]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[7]  K. Überla,et al.  Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity , 2008, BMC Immunology.

[8]  C. Russell Middaugh,et al.  Nanotechnology in vaccine delivery☆ , 2008, Advanced Drug Delivery Reviews.

[9]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[10]  Magdalena Plebanski,et al.  Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. , 2006, Methods.

[11]  Qiang Liu,et al.  Molecular basis of the inflammatory response to adenovirus vectors , 2003, Gene Therapy.

[12]  W. Egan,et al.  Corrigendum to “Aluminum salts in vaccines—US perspective” [Vaccine 20 (Suppl. 2) (2002) S18–S23] , 2002 .

[13]  Paul Richman,et al.  Aluminum salts in vaccines--US perspective. , 2002, Vaccine.

[14]  K. Zatloukal,et al.  High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Peter Walden,et al.  Exact prediction of a natural T cell epitope , 1991, European journal of immunology.

[16]  S. Elsayed,et al.  Antigenic and allergenic determinants of ovalbumin--III. MHC Ia-binding peptide (OA 323-339) interacts with human and rabbit specific antibodies. , 1990, Molecular immunology.

[17]  H. Waldmann,et al.  Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo , 1984, Nature.